文献速递外周动脉疾病

药物洗脱支架(Zilver PTX)治疗股腘动脉闭塞性疾病的单中心临床结果

Clinical Outcome of Drug-Eluted Stenting (Zilver PTX) in Patients With Femoropopliteal Occlusive Disease a Single Center Experience.
PubMed 文献 · J Endovasc Ther · 2021-10-08

单中心回顾性分析115条肢体接受Zilver PTX治疗,68%为CLTI,平均病变长度21cm,68%为完全闭塞。TASC A-C病变1年与2年一期通畅率分别为94%和88%,TASC D病变为50%和16%(p<0.0001)。结论认为该支架对TASC A-C病变效果满意,对TASC D病变效果不佳。

要点

  • TASC A-C病变Zilver PTX术后2年一期通畅率88%,TASC D仅16%。
  • CLTI患者1年MAE发生率52%,显著高于间歇性跛行患者的30%(p=0.0392)。
  • TASC D病变2年免于MALE率仅50%,应谨慎选择支架治疗。

核心结论

  • Zilver PTX治疗股腘动脉病变对TASC A-C病变临床结果满意,对TASC D病变结果较差/不满意。

研究设计与样本

  • 单中心回顾性分析115条接受Zilver PTX治疗的肢体,平均随访18.4个月(范围1-76个月)。

主要发现

  • 1年MALE率为17%(跛行13.5% vs CLTI 19.2%,p=0.4499),MAE率跛行30% vs CLTI 52%(p=0.0392)。
  • 总体1年与2年一期通畅率分别为75%和54%(跛行86%和71% vs CLTI 70%和46%,p=0.0213)。
  • TASC A-C病变1年与2年一期通畅率94%和88%,TASC D病变50%和16%(p<0.0001)。
  • 总体1年与2年免于MALE率85%和79%;TASC A-C为96%和93%,TASC D为70%和50%(p<0.0001)。
  • 1年与2年保肢率93%和86%(跛行100%和100% vs CLTI 89%和78%,p=0.012);AFS 79%和71%(TASC A-C 93%和82% vs TASC D 59%和59%,p=0.001)。

临床怎么用

  • 对于TASC A-C股腘动脉病变,Zilver PTX可作为治疗选择之一。
  • 对于TASC D病变,应预期支架通畅率低,需谨慎选择或考虑其他治疗策略。
  • CLTI患者术后MAE和保肢不良事件风险显著高于跛行患者,需加强围术期管理。

局限性

  • 单中心真实世界研究,样本量有限,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few industry sponsored trials reported satisfactory outcomes in the use of drug-eluting stents (DES) for treatment of femoropopliteal arterial disease. This study analyzed the early/late clinical outcome from a real world single center. PATIENT POPULATIONS/METHODS: A total of 115 limbs treated with Zilver PTX were analyzed for: major adverse limb event (MALE: above ankle limb amputation/major intervention at 1 year), major adverse events (MAEs; death, amputation, and target lesion thrombosis/reintervention), primary patency (based on duplex ultrasound ± ankle brachial indexes), limb salvage, and amputation free survival rates (AFS) at 1 and 2 years. RESULTS: Indications included claudication in 32% and critical limb threatening ischemia (CLTI) in 68%. Lesions treated included: superficial femoral artery (SFA) 66%, both SFA and popliteal artery (PA) 19% and PA 15%. Mean lesion length was 21 cm and 68% had total occlusion. 45% were Trans-Atlantic Inter-Society Consensus (TASC) TASC II D lesions and 55% A-C lesions. Mean follow-up was 18.4 months (1-76 months). Perioperative major morbidity rate was 8.7% with 0% mortality. MALE rate at 1 year was 17% (13.5% for claudication vs 19.2% for CLTI, p=0.4499). MAE rate was 30% for claudication versus 52% for CLTI (p=0.0392). Overall primary patency rates at 1 and 2 years were 75% and 54% (86% and 71% for claudication vs 70% and 46% for CLTI, respectively, p=0.0213). Primary patency rates at 1 and 2 years were 94% and 88% for TASC A-C lesions versus 50% and 16% for TASC D lesions (p<0.0001). Overall freedom from MALE rate at 1 and 2 years were 85% and 79% (86% and 86% for claudication vs 84% and 74% for CLTI, p=0.2391). These rates were 96% and 93% for TASC A-C lesions versus 70% and 50% for D lesions, respectively (p<0.0001). Limb salvage rates at 1 and 2 years were 93% and 86% (100% and 100% for claudication vs 89% and 78% for CLTI, p=0.012). Overall AFS rates at 1 and 2 years were 79% and 71% (93% and 82% for TASC A-C vs 59% and 59% for D lesions, p=0.001). CONCLUSION: Clinical outcomes after DES (Zilver PTX) in femoropopliteal arterial lesions were satisfactory for TASC A-C lesions but inferior/unsatisfactory for TASC D lesions.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. AbuRahma AF, Beasley M, AbuRahma ZT, et al. Clinical Outcome of Drug-Eluted Stenting (Zilver PTX) in Patients With Femoropopliteal Occlusive Disease a Single Center Experience. J Endovasc Ther. 2021. PMID: 34622706. doi:10.1177/15266028211049339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。